drugset / Trial / NCT00030355

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

NCT00030355

Phase 1/2 Withdrawn National Cancer Institute (NCI)
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of homoharringtonine in treating patients who have refractory acute promyelocytic leukemia.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Homoharringtonine Small molecule Intravenous

Indications